BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/4/2018 1:15:45 PM | Browse: 792 | Download: 908
Publication Name World Journal of Gastroenterology
Manuscript ID 38160
Country/Territory Japan
Received
2018-02-05 06:01
Peer-Review Started
2018-02-05 06:28
To Make the First Decision
2018-02-24 01:21
Return for Revision
2018-02-26 03:37
Revised
2018-02-26 07:33
Second Decision
2018-03-06 09:43
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2018-03-06 16:59
Articles in Press
2018-03-06 16:59
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2018-04-03 05:48
Publish the Manuscript Online
2018-04-04 13:15
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Prospective Study
Article Title Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus
Manuscript Source Unsolicited Manuscript
All Author List Masayoshi Yada, Masayuki Miyazaki, Kosuke Tanaka, Akihide Masumoto and Kenta Motomura
ORCID
Author(s) ORCID Number
Masayoshi Yada http://orcid.org/0000-0002-1129-5380
Masayuki Miyazaki http://orcid.org/0000-0002-4192-8150
Kosuke Tanaka http://orcid.org/0000-0003-1472-0597
Akihide Masumoto http://orcid.org/0000-0003-4929-6271
Kenta Motomura http://orcid.org/0000-0002-7515-099X
Funding Agency and Grant Number
Corresponding Author Masayoshi Yada, MD, PhD, Doctor, Department of Hepatology, Iizuka Hospital, 3-83 Yoshio-machi, Iizuka 820-8505, Fukuoka, Japan. myadah1@aih-net.com
Key Words Sofosbuvir; Ribavirin; Genotype 2; Hepatitis C virus; Interferon-based therapy; Hepatocellular carcinoma
Core Tip The real-world efficacy of sofosbuvir/ribavirin therapy for genotype 2 hepatitis C virus infection in Japan is high. Sofosbuvir/ribavirin therapy is safe and highly tolerated. History of hepatocellular carcinoma or interferon-based therapy independently reduces the efficacy of sofosbuvir/ribavirin therapy. Progressive liver fibrosis may attenuate the antiviral effect of sofosbuvir/ribavirin therapy.
Publish Date 2018-04-04 13:15
Citation Yada M, Miyazaki M, Tanaka K, Masumoto A, Motomura K. Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus. World J Gastroenterol 2018; 24(13): 1478-1485
URL http://www.wjgnet.com/1007-9327/full/v24/i13/1478.htm
DOI http://dx.doi.org/10.3748/wjg.v24.i13.1478
Full Article (PDF) WJG-24-1478.pdf
Full Article (Word) WJG-24-1478.doc
Manuscript File 38160-Review.docx
Answering Reviewers 38160-Answering reviewers.pdf
Audio Core Tip 38160-Audio core tip.mp3
Biostatistics Review Certificate 38160-Biostatistics statement.pdf
Clinical Trial Registration Statement 38160-Clinical Trial Registration Statement.pdf
Conflict-of-Interest Disclosure Form 38160-Conflict-of-interest statement.pdf
Copyright License Agreement 38160-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s) 38160-Informed consent statement.pdf
Institutional Review Board Approval Form or Document 38160-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate 38160-Language certificate.pdf
Peer-review Report 38160-Peer-review(s).pdf
Scientific Misconduct Check 38160-Scientific misconduct check.pdf
Scientific Editor Work List 38160-Scientific editor work list.pdf